Ikonisys Announces the First Sale of the Ikoniscope20max Solution
21 Juin 2023 - 6:57PM
Business Wire
Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO)
(Paris:ALIKO), a company specializing in the early and accurate
detection of cancer with a unique fully-automated solution for
medical diagnostic labs, announces the first successful sale and
installation of the Ikoniscope20max, the new configuration of the
Ikoniscope20 with a high-volume slide loader. The client is a large
volume, specialized urology laboratory, located in the Midwest
USA.
The Ikoniscope20max allows laboratories to automatically process
up to 160 FISH slides without any further human intervention. By
way of example, the operator of a laboratory processing hundreds of
slides per week could load the full rack of 160 slides on a Friday
afternoon and start the scanning. On Monday morning they will find
all those slides analyzed and reported.
The Ikoniscope20max provides the same performance as the
Ikoniscope20 both in terms of speed and accuracy of the results and
the instrument has been shown to continue providing better
performances if used in combination with Ikonisys optimized FISH
reagents.
This development follows the timeline presented by the
management during the IPO, allowing the company to address a
broader market consisting of laboratories that process a very large
number of slides per week or that have specific needs in terms of
timing.
Mario Crovetto, CEO of Ikonisys stated: “This milestone will
support the solid growth expected for the current year and we are
looking forward to pursuing the deployment of our commercial
strategy which is now producing its first tangible results”.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621104981/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024